Early findings from the ongoing phase 1/2 AMPLIFY-7P trial suggest that the investigational vaccine ELI-002 7P could represent a breakthrough in treating pancreatic ductal adenocarcinoma (PDAC), one of the most challenging cancers to treat. The vaccine, designed to target multiple $KRAS$ mutations, has shown a strong and consistent ability to stimulate the immune system in […]
Researchers have created a promising new combination immunotherapy that could improve treatment for ovarian cancer, a disease that often resists standard immunotherapies. The study combines two immune-based treatments to produce a stronger and longer-lasting anti-tumor response. The first component uses engineered T cells that specifically target the folate receptor alpha, a protein found in abundance
New Dual Immunotherapy Shows Promise for Ovarian Cancer Read More »
A new machine learning model has been developed to predict the risk of secondary cancers in patients who have undergone radiation therapy. These secondary cancers can appear years later due to the effects of ionizing radiation. The model, a Random Forest Regressor, uses data from clinical, pathology, and genomic sources—such as cancer type, age, radiation
AI Model Accurately Predicts Secondary Cancer Risk After Radiation Therapy Read More »
The phase 3 VIKTORIA-1 trial showed that treatment regimens including gedatolisib significantly improved outcomes for patients with hormone receptor–positive, HER2-negative, and PIK3CA wild-type metastatic breast cancer that had progressed after CDK4/6 inhibitor therapy. Patients who received the triplet regimen (gedatolisib, palbociclib, and fulvestrant) had a median progression-free survival (PFS) of 9.3 months compared to 2.0
Gedatolisib Regimens Significantly Extend Survival in Advanced Breast Cancer Read More »
Toripalimab-tpzi (Loqtorzi) has been approved as the first and only immunotherapy for recurrent, unresectable, or metastatic nasopharyngeal carcinoma (NPC). It can be used in combination with cisplatin and gemcitabine as a first-line treatment for metastatic or recurrent locally advanced NPC, or as a single drug for patients whose disease has progressed after platinum-based chemotherapy. The
Toripalimab (Loqtorzi) Approved as First Immunotherapy for Nasopharyngeal Carcinoma Read More »
The INTERCEPT CRC study showed that clearing circulating tumor DNA (ctDNA) after adjuvant therapy is a powerful indicator of better outcomes in patients with resectable stage I–IV colorectal cancer. Researchers found that among patients who were ctDNA-positive after surgery, 26% achieved ctDNA clearance following adjuvant treatment. These patients had significantly longer disease-free survival compared to
Clearing ctDNA After Therapy Linked to Longer Survival in Colorectal Cancer Read More »
Montanide ISA-51 is a water-in-oil emulsion adjuvant derived from Freund’s incomplete adjuvant and is designed to enhance immune responses in cancer vaccines with lower toxicity. It works by forming an oil depot at the injection site, allowing slow and sustained release of the antigen for prolonged immune stimulation. This process recruits immune cells like dendritic
Bladder cancer (BCa) is classified by tumor spread: non-muscle invasive (~75%), muscle-invasive (~20%), and metastatic (~5%). Non-muscle invasive BCa is treated with transurethral resection (TURBT), often followed by a single chemotherapy dose for low-risk cases or Bacillus Calmette–Guérin (BCG) immunotherapy for higher-risk patients. BCG can cause toxicity and recurrence remains high. Muscle-invasive disease is treated
Suppressor Cells Linked to Bladder Cancer Progression and Treatment Resistance Read More »
Skin cancer includes melanoma (MSC) and non-melanoma types (NMSC) such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Melanoma is less common but more deadly, with about 324,000 new cases and 57,000 deaths annually. NMSCs are far more common, especially BCC, though SCC causes most related deaths. Conventional treatments like surgery, radiation, chemotherapy,
Nanotechnology Paves the Way for Next-Generation Skin Cancer Treatments Read More »
The final results of the Phase 3 COMPASSION-15 trial confirmed that cadonilimab, a bispecific PD-1/CTLA-4 antibody, combined with XELOX chemotherapy offers a significant long-term survival benefit for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma compared to XELOX alone. After a median follow-up of 33.9 months, patients treated with cadonilimab plus XELOX achieved a